30 closest matches · ranked by relevance
Adult Acute Myeloid Leukemia · Secondary Acute Myeloid Leukemia · Therapy-Related Acute Myeloid Leukemia
Primary: Rate of Complete Remission and Mortality in the Entire Cohort of Older Patients — 21.9; 52.0 percentage of subjects
Leukemia, Myeloid, Acute
Primary: Number of Participants With a Complete Response (CR) — 79; 71 Participants — p=0.482
Leukemia, Myeloid, Acute
Primary: Complete Remission Rate (CRm + CRi + CRc) — 0; 3; 0; 4 participants
Novo Acute Myeloid Leukemia
Primary: Complete Remission of the Disease — NA; 18; 16; NA Participants
Leukemia, Myeloid, Acute
Primary: Phase I Only - Maximum Tolerated Dose (MTD) as Measured by Dose-limiting Toxicities (DLTs) — 1; 0; 0 dose-limiting toxicities
Acute Myelogenous Leukemia
Primary: Percentage of Participants With Relapse Free Survival at 1 Year — 56 percentage of participants
Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities · Adult Acute Myeloid Leukemia With Del(5q) · Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)
Primary: Rate of Complete Remission — 25 patients
Acute Myeloid Leukemia · Myelodysplastic Syndrome · Myelodysplastic Syndrome/Acute Myeloid Leukemia
Primary: Overall Survival (OS) (Phase II) — 6.2; 5.2; 7.4 months
Leukemia · Acute Disease · Acute Myeloid Leukemia
Primary: Remission Rate Defined as the Percentage of Patients Whose Respnse is CR or CRp Based on International Working Group (IWG) Response Criteria and Treatment Outcomes…
Leukemia, Myeloid
Primary: Response Rate (CR + CRi + LFS) — 3; 10 participants
Leukemia, Myelocytic, Acute
Primary: Minimal Residual Disease (MRD). — 31; 43; 68; 63 participants — p=.1559
Acute Myeloid Leukemia
Primary: Maximum Tolerated Dose (MTD) of Gemtuzumab Ozogamicin (GO) When Added to GCLAM (Phase 1) — NA; NA Participants
Relapsed Acute Myeloid Leukemia
Primary: Feasibility of a Novel Combination of Pembrolizumab and Decitabine in Relapsed/Refractory Acute Myeloid Leukemia Participants — 10 Participants
Acute Lymphoblastic Leukemia
Primary: Overall Survival at One Year — 19 Participants
Acute Myeloid Leukemia (AML) · Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome · Acute Myeloid Leukemia With Multilineage Dysplasia
Primary: Complete Remission Rate (CR) — 20 Participants
Leukemia, Myeloid, Acute
Primary: Primary Efficacy — 7 Participants
Leukemia
Primary: Continuous Complete Remission at 3 Years — 74 percentage of participants
Acute Myeloid Leukemia
Primary: Percentage of Participants With Complete Remission or Complete Remission With Incomplete Recovery Blood Counts — 11 percentage of participants
Acute Myeloid Leukemia (AML)
Primary: Event-Free Survival (EFS) — 11.24; 7.72 months — p==0.477
Acute Myeloid Leukemia
Primary: Number of Participants by Best Clinical Response Experienced — 20; 6; 6; 7 Participants
Acute Myeloid Leukemia (AML)
Primary: Overall Survival (OS) — 9.6; 14.7 months — p=<0.001
Leukemia
Primary: Overall Survival (Induction Phase) — 15.7; 23.7 months
Leukemia
Primary: Rate of Disease Free Survival at One Year — 50 percentage of participants
Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome · Adult Acute Minimally Differentiated Myeloid Leukemia (M0) · Adult Acute Monoblastic Leukemia (M5a)
Primary: Complete Response Rate — 76; 24 participants
Leukemia · Acute Myeloid Leukemia · AML
Primary: Complete Response (CR) Rate — 98; 4; 9; 7 Participants
Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome · Adult Acute Megakaryoblastic Leukemia (M7) · Adult Acute Minimally Differentiated Myeloid Leukemia (M0)
Primary: Complete Response — 0; 0 participants
Acute Myeloid Leukemia · Acute Myeloid Leukemia With Myelodysplasia-Related Changes · Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11
Primary: Number of Participants Who Completed Maintenance Decitabine. — 62 participants
Leukemia, Myeloid, Acute
Primary: The Maximum Tolerated Dose (MTD) of 2 Schedules of BI 811283 in Combination With Cytarabine. — 100; NA mg
Adult Acute Basophilic Leukemia · Adult Acute Eosinophilic Leukemia · Adult Acute Megakaryoblastic Leukemia (M7)
Primary: Complete Response — 11 percentage of participants
Leukemia
Primary: 2-year Disease-free Survival (DFS) — 39; 50 Percentage of population — p=<0.001